Gene Signal promise for topical AMD antisense treatment
This article was originally published in Scrip
Gene Signal's topical anti-angiogenic eye therapy aganirsen could be effective in preventing vascularisation at the back of the eye, new data suggest, potentially opening up a new way of treating diseases such as wet AMD and ischaemic retinopathy.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.